- 2024 Reporting PeriodCMS104v12STK-2
]]>Not ApplicableIschemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge
]]>
None
]]>Inpatient hospitalizations for patients age 18 and older, discharged from inpatient care (non-elective admissions) with a principal diagnosis of ischemic or hemorrhagic stroke and a length of stay less than or equal to 120 days that ends during the measurement period
]]>Inpatient hospitalizations for patients prescribed or continuing to take antithrombotic therapy at hospital discharge
]]>Not Applicable
]]>Inpatient hospitalizations for patients with a principal diagnosis of ischemic stroke
]]>- Inpatient hospitalizations for patients admitted for elective carotid intervention. This exclusion is implicitly modeled by only including non-elective hospitalizations.
- Inpatient hospitalizations for patients discharged to another hospital
- Inpatient hospitalizations for patients who left against medical advice
- Inpatient hospitalizations for patients who expired
- Inpatient hospitalizations for patients discharged to home for hospice care
- Inpatient hospitalizations for patients discharged to a health care facility for hospice care
- Inpatient hospitalizations for patients with comfort measures documented
]]>- Inpatient hospitalizations for patients with a documented reason for not prescribing antithrombotic therapy at discharge
- Inpatient hospitalizations for patients who receive Prasugrel as an antithrombotic therapy at discharge
]]>The Joint Commission]]>Proportion]]>Process]]>Improvement noted as an increase in rate
]]>The "Nonelective Inpatient Encounter" value set intends to capture all non-scheduled hospitalizations. This value set is a subset of the "Inpatient encounter" value set, excluding concepts that specifically refer to elective hospital admissions. Non-elective admissions include emergency, urgent and unplanned admissions.The "Medication, Discharge" datatype refers to the discharge medication list and is intended to express medications ordered for post-discharge use.The denominator population includes patients with inpatient hospitalizations and patients from Acute Hospital Care at Home programs, who are treated and billed as inpatients but receive care in their home.This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period.This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.The effectiveness of antithrombotic agents in reducing stroke mortality, stroke-related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity as long as no contraindications exist.
For patients with a stroke due to a cardioembolic source (e.g., atrial fibrillation, mechanical heart valve), warfarin is recommended unless contraindicated. In recent years, novel oral anticoagulant agents (NOACs) have been developed and approved by the U.S. Food and Drug Administration (FDA) for stroke prevention, and may be considered as an alternative to warfarin for select patients. Anticoagulation therapy is not generally recommended for secondary stroke prevention in patients presumed to have a non-cardioembolic stroke.
Anticoagulants at doses to prevent venous thromboembolism are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or transient ischemic attack (TIA).
]]>None
]]>None
]]>Clinical trial results suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity as long as no contraindications exist
]]> - 2025 Reporting PeriodCMS104v13STK-2
]]>Not ApplicableIschemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge]]>None]]>Inpatient hospitalizations (non-elective admissions) for patients age 18 and older, discharged from inpatient care with a principal diagnosis of ischemic stroke, ending during the measurement period]]>Inpatient hospitalizations for patients prescribed or continuing to take antithrombotic therapy at hospital discharge]]>Not Applicable]]>Equals Initial Population]]>- Inpatient hospitalizations for patients admitted for elective carotid intervention. This exclusion is implicitly modeled by only including non-elective hospitalizations.
- Inpatient hospitalizations for patients discharged to another hospital
- Inpatient hospitalizations for patients who left against medical advice
- Inpatient hospitalizations for patients who expired
- Inpatient hospitalizations for patients discharged to home for hospice care
- Inpatient hospitalizations for patients discharged to a health care facility for hospice care
- Inpatient hospitalizations for patients with comfort measures documented
]]>- Inpatient hospitalizations for patients with a documented reason for not prescribing antithrombotic therapy at discharge- Inpatient hospitalizations for patients who receive Prasugrel as an antithrombotic therapy at discharge
]]>The Joint Commission]]>Proportion]]>Process]]>Improvement noted as an increase in rate]]>The "Nonelective Inpatient Encounter" value set intends to capture all non-scheduled hospitalizations. This value set is a subset of the "Inpatient encounter" value set, excluding concepts that specifically refer to elective hospital admissions. Non-elective admissions include emergency, urgent and unplanned admissions.The "Medication, Discharge" datatype refers to the discharge medication list and is intended to express medications ordered for post-discharge use.The denominator population includes patients with inpatient hospitalizations and patients from Acute Hospital Care at Home programs, who are treated and billed as inpatients but receive care in their home.This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period.This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.The effectiveness of antithrombotic agents in reducing stroke mortality, stroke-related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity if no contraindications exist.For patients with a stroke due to a cardioembolic source (e.g., atrial fibrillation, mechanical heart valve), warfarin is recommended unless contraindicated. In recent years, novel oral anticoagulant agents (NOACs) have been developed and approved by the U.S. Food and Drug Administration (FDA) for stroke prevention and may be considered as an alternative to warfarin for select patients. Anticoagulation therapy is not generally recommended for secondary stroke prevention in patients presumed to have a non-cardioembolic stroke.
Anticoagulants at doses to prevent venous thromboembolism are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or transient ischemic attack (TIA).
]]>None]]>None]]>Clinical trial results suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity if no contraindications exist]]> - 2026 Reporting PeriodCMS104v14STK-2
]]>Not ApplicableIschemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge]]>None]]>Inpatient hospitalizations (non-elective admissions) for patients age 18 and older, discharged from inpatient care with a principal diagnosis of ischemic stroke, ending during the measurement period]]>Inpatient hospitalizations for patients prescribed or continuing to take antithrombotic therapy at hospital discharge]]>None]]>Equals Initial Population]]>- Inpatient hospitalizations for patients admitted for elective carotid intervention. This exclusion is implicitly modeled by only including non-elective hospitalizations.
- Inpatient hospitalizations for patients discharged to another hospital
- Inpatient hospitalizations for patients who left against medical advice
- Inpatient hospitalizations for patients who expired
- Inpatient hospitalizations for patients discharged to home for hospice care
- Inpatient hospitalizations for patients discharged to a health care facility for hospice care
- Inpatient hospitalizations for patients with comfort measures documented
]]>- Inpatient hospitalizations for patients with a documented reason for not prescribing antithrombotic therapy at discharge- Inpatient hospitalizations for patients who receive Prasugrel as an antithrombotic therapy at discharge
]]>The Joint Commission]]>Proportion]]>Process]]>Increased score indicates improvement]]>The "Nonelective Inpatient Encounter" value set intends to capture all non-scheduled hospitalizations. This value set is a subset of the "Inpatient encounter" value set, excluding concepts that specifically refer to elective hospital admissions. Non-elective admissions include emergency, urgent and unplanned admissions.The "Medication, Discharge" datatype refers to the discharge medication list and is intended to express medications ordered for post-discharge use.The denominator population includes patients with inpatient hospitalizations and patients from Acute Hospital Care at Home programs, who are treated and billed as inpatients but receive care in their home.This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period.This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.The effectiveness of antithrombotic agents in reducing stroke mortality, stroke-related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity if no contraindications exist.For patients with a stroke due to a cardioembolic source (e.g., atrial fibrillation, mechanical heart valve), warfarin is recommended unless contraindicated. In recent years, novel oral anticoagulant agents (NOACs) have been developed and approved by the U.S. Food and Drug Administration (FDA) for stroke prevention and may be considered as an alternative to warfarin for select patients. Anticoagulation therapy is not generally recommended for secondary stroke prevention in patients presumed to have a non-cardioembolic stroke.
Anticoagulants at doses to prevent venous thromboembolism are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or transient ischemic attack (TIA).
]]>None]]>None]]>Clinical trial results suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity if no contraindications exist]]>